Table 11.
Association of PSRC1, CELSR2, and SORT1 SNPs with Warfarin Responsiveness During the Stabilization Phase of Therapy of 139 Cardiovascular Patients Treated with Warfarin
| Gene | SNP ID | Genotype | Poora (n= 9) | Goodb (n= 124) | Ultrac (n= 6) | Overall P-value* |
|---|---|---|---|---|---|---|
| PSRC1 | rs646776 | CC | (0/6) 0.0% | (6/6) 100% | (0/6) 0.0% | 0.715 |
| P-value* | 0.48 | 0.37 | 0.62 | |||
| CT | (2/48) 4.2% | (43/48) 89.6% | (3/48) 6.3% | |||
| P-value* | 0.42 | 0.92 | 0.42 | |||
| TT | (7/85) 8.2% | (75/85) 88.2% | (3/85) 3.5% | |||
| P-value* | 0.27 | 0.62 | 0.55 | |||
| CELSR2 | rs660240 | CC | (7/83) 8.4% | (73/83) 88% | (3/83) 3.6% | 0.718 |
| P-value* | 0.32 | 0.69 | 0.55 | |||
| TC | (2/46) 4.3% | (41/46) 89.1% | (3/46) 6.5% | |||
| P-value* | 0.42 | 0.92 | 0.42 | |||
| TT | (0/6) 0.0% | (6/6) 100% | (0/6) 0.0% | |||
| P-value* | 0.48 | 0.37 | 0.62 | |||
| rs12740374 | GG | (7/89) 7.9% | (79/89) 88.8% | (3/89) 3.4% | 0.766 | |
| P-value* | 0.37 | 0.84 | 0.42 | |||
| GT | (2/44) 4.5% | (39/44) 88.6% | (3/44) 6.8% | |||
| P-value* | 0.55 | 0.92 | 0.32 | |||
| TT | (0/5) 0.0% | (5/5) 100% | (0/5) 0.0% | |||
| P-value* | 0.55 | 0.42 | 0.62 | |||
| SORT1 | rs602633 | GG | (7/79) 8.9% | (69/79) 87.3% | (3/79) 3.8% | 0.691 |
| P-value* | 0.19 | 0.27 | 0.92 | |||
| GT | (2/50) 4% | (46/50) 92% | (2/50) 4% | |||
| P-value* | 0.37 | 0.55 | 0.84 | |||
| TT | (0/9) 0.0% | (9/9) 100% | (0/9) 0.0% | |||
| P-value* | 0.42 | 0.32 | 0.55 |
Notes: *Chi-square test with p< 0.05 is considered significant. a Poor responders (international normalized ratio (INR) value below target). b Good responders who have an INR in the target range (therapeutic range). c Ultra-responders (INR over target).